Literature DB >> 26700676

Glutamine at focus: versatile roles in cancer.

Humberto De Vitto1, Juan Pérez-Valencia2, James A Radosevich3.   

Abstract

During the past decade, a heightened understanding of metabolic pathways in cancer has significantly increased. It is recognized that many tumor cells are genetically programmed and have involved an abnormal metabolic state. Interestingly, this increased metabolic autonomy generates dependence on various nutrients such as glucose and glutamine. Both of these components participate in various facets of metabolic activity that allow for energy production, synthesis of biomass, antioxidant defense, and the regulation of cell signaling. Here, we outline the emerging data on glutamine metabolism and address the molecular mechanisms underlying glutamine-induced cell survival. We also discuss novel therapeutic strategies to exploit glutamine addiction of certain cancer cell lines.

Entities:  

Keywords:  Cancer; Glutamine; Oncogene; Targeting glutamine metabolism; Tumor suppressor

Mesh:

Substances:

Year:  2015        PMID: 26700676     DOI: 10.1007/s13277-015-4671-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  165 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine.

Authors:  A Bröer; C A Wagner; F Lang; S Bröer
Journal:  Biochem J       Date:  2000-08-01       Impact factor: 3.857

3.  Amino acid, glucose, and lactic acid utilization in vivo by rat tumors.

Authors:  L A Sauer; J W Stayman; R T Dauchy
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

Review 4.  Cell biology. Metabolic control of cell death.

Authors:  Douglas R Green; Lorenzo Galluzzi; Guido Kroemer
Journal:  Science       Date:  2014-09-19       Impact factor: 47.728

5.  PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4-fluoroglutamine.

Authors:  Brian P Lieberman; Karl Ploessl; Limin Wang; Wenchao Qu; Zhihao Zha; David R Wise; Lewis A Chodosh; George Belka; Craig B Thompson; Hank F Kung
Journal:  J Nucl Med       Date:  2011-11-15       Impact factor: 10.057

6.  The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type.

Authors:  Mariia O Yuneva; Teresa W M Fan; Thaddeus D Allen; Richard M Higashi; Dana V Ferraris; Takashi Tsukamoto; José M Matés; Francisco J Alonso; Chunmei Wang; Youngho Seo; Xin Chen; J Michael Bishop
Journal:  Cell Metab       Date:  2012-02-08       Impact factor: 27.287

Review 7.  How cancer metabolism is tuned for proliferation and vulnerable to disruption.

Authors:  Almut Schulze; Adrian L Harris
Journal:  Nature       Date:  2012-11-15       Impact factor: 49.962

Review 8.  Cancer metabolism: current perspectives and future directions.

Authors:  C Muñoz-Pinedo; N El Mjiyad; J-E Ricci
Journal:  Cell Death Dis       Date:  2012-01-12       Impact factor: 8.469

9.  Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ß-lapachone.

Authors:  Gaurab Chakrabarti; Zachary R Moore; Xiuquan Luo; Mariya Ilcheva; Aktar Ali; Mahesh Padanad; Yunyun Zhou; Yang Xie; Sandeep Burma; Pier P Scaglioni; Lewis C Cantley; Ralph J DeBerardinis; Alec C Kimmelman; Costas A Lyssiotis; David A Boothman
Journal:  Cancer Metab       Date:  2015-10-12

Review 10.  Overview on how oncogenic Kras promotes pancreatic carcinogenesis by inducing low intracellular ROS levels.

Authors:  Bo Kong; Chengjia Qia; Mert Erkan; Jörg Kleeff; Christoph W Michalski
Journal:  Front Physiol       Date:  2013-09-12       Impact factor: 4.566

View more
  18 in total

Review 1.  Cancer Cell Metabolism: Implications for X-ray and Particle Radiation Therapy.

Authors:  Mathieu Sertorio; John P Perentesis; Ralph E Vatner; Anthony E Mascia; Yi Zheng; Susanne I Wells
Journal:  Int J Part Ther       Date:  2018-09-21

Review 2.  Targeting metabolic vulnerabilities of cancer: Small molecule inhibitors in clinic.

Authors:  Satyendra C Tripathi; Johannes F Fahrmann; Jody V Vykoukal; Jennifer B Dennison; Samir M Hanash
Journal:  Cancer Rep (Hoboken)       Date:  2018-09-23

3.  Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

Review 4.  Mitochondria and Cancer.

Authors:  Wei-Xing Zong; Joshua D Rabinowitz; Eileen White
Journal:  Mol Cell       Date:  2016-03-03       Impact factor: 17.970

Review 5.  Minireview on Glutamine Synthetase Deficiency, an Ultra-Rare Inborn Error of Amino Acid Biosynthesis.

Authors:  Marta Spodenkiewicz; Carmen Diez-Fernandez; Véronique Rüfenacht; Corinne Gemperle-Britschgi; Johannes Häberle
Journal:  Biology (Basel)       Date:  2016-10-19

Review 6.  Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging.

Authors:  Nirilanto Ramamonjisoa; Ellen Ackerstaff
Journal:  Front Oncol       Date:  2017-01-31       Impact factor: 6.244

7.  Salivary metabolite profiling distinguishes patients with oral cavity squamous cell carcinoma from normal controls.

Authors:  Pawadee Lohavanichbutr; Yuzheng Zhang; Pei Wang; Haiwei Gu; G A Nagana Gowda; Danijel Djukovic; Matthew F Buas; Daniel Raftery; Chu Chen
Journal:  PLoS One       Date:  2018-09-20       Impact factor: 3.240

8.  Targeted inhibition of glutaminase as a potential new approach for the treatment of NF1 associated soft tissue malignancies.

Authors:  Tahir N Sheikh; Parag P Patwardhan; Serge Cremers; Gary K Schwartz
Journal:  Oncotarget       Date:  2017-10-06

Review 9.  Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy.

Authors:  Ana Cavaco; Maryam Rezaei; Stephan Niland; Johannes A Eble
Journal:  Int J Mol Sci       Date:  2017-11-07       Impact factor: 5.923

Review 10.  The Novel Roles of Connexin Channels and Tunneling Nanotubes in Cancer Pathogenesis.

Authors:  Silvana Valdebenito; Emil Lou; John Baldoni; George Okafo; Eliseo Eugenin
Journal:  Int J Mol Sci       Date:  2018-04-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.